Results
1271
Companies which are more than 50% undervalued based on analyst price target.
1,271 companies
UnitedHealth Group
Market Cap: US$343.6b
Operates as a health care company in the United States and internationally.
UNH
US$311.38
7D
-21.1%
1Y
-39.4%
Marvell Technology
Market Cap: US$55.9b
Provides data infrastructure semiconductor solutions, spanning the data center core to network edge.
MRVL
US$65.48
7D
7.0%
1Y
-3.7%
Summit Therapeutics
Market Cap: US$18.8b
A biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies.
SMMT
US$24.61
7D
1.7%
1Y
425.3%
Kaspi.kz
Market Cap: US$15.8b
Provides payments, marketplace, and fintech solutions for consumers and merchants in Kazakhstan, Azerbaijan, and Ukraine.
KSPI
US$80.74
7D
-9.5%
1Y
-32.7%
BioMarin Pharmaceutical
Market Cap: US$11.5b
A biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.
BMRN
US$59.78
7D
0.8%
1Y
-25.6%
Moderna
Market Cap: US$9.9b
A biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally.
MRNA
US$25.49
7D
4.3%
1Y
-80.1%
AST SpaceMobile
Market Cap: US$8.9b
Designs and develops the constellation of BlueBird satellites in the United States.
ASTS
US$26.55
7D
5.9%
1Y
957.8%
VinFast Auto
Market Cap: US$8.8b
Engages in the design and manufacture of electric vehicles (EV), e-scooters, and e-buses in Vietnam, Canada, and the United States.
VFS
US$3.72
7D
0.8%
1Y
-9.5%
Roivant Sciences
Market Cap: US$7.8b
A commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas.
ROIV
US$10.76
7D
-2.7%
1Y
-5.0%
Corcept Therapeutics
Market Cap: US$7.7b
Engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
CORT
US$70.59
7D
-0.2%
1Y
155.2%
Revolution Medicines
Market Cap: US$7.4b
A clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers.
RVMD
US$39.95
7D
6.7%
1Y
6.9%
UWM Holdings
Market Cap: US$6.8b
Engages in the origination, sale, and servicing residential mortgage lending in the United States.
UWMC
US$4.24
7D
4.2%
1Y
-42.3%
BridgeBio Pharma
Market Cap: US$6.8b
A commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers.
BBIO
US$33.26
7D
-10.0%
1Y
14.9%
Jazz Pharmaceuticals
Market Cap: US$6.4b
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally.
JAZZ
US$102.91
7D
-7.4%
1Y
-8.1%
GDS Holdings
Market Cap: US$5.8b
Develops and operates data centers in the People's Republic of China.
GDS
US$27.34
7D
-2.6%
1Y
224.7%
EchoStar
Market Cap: US$5.8b
Provides networking technologies and services in the United States and internationally.
SATS
US$19.78
7D
-17.3%
1Y
18.1%
Legend Biotech
Market Cap: US$5.7b
Through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.
LEGN
US$31.08
7D
-1.2%
1Y
-32.1%
Lantheus Holdings
Market Cap: US$5.5b
Develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide.
LNTH
US$78.95
7D
-24.7%
1Y
0.3%
Axsome Therapeutics
Market Cap: US$5.4b
A biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.
AXSM
US$105.67
7D
-5.8%
1Y
36.6%
Ionis Pharmaceuticals
Market Cap: US$5.3b
A commercial-stage biotechnology company, provides RNA-targeted medicines in the United States.
IONS
US$32.53
7D
2.1%
1Y
-15.0%
Nuvalent
Market Cap: US$5.3b
A clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer.
NUVL
US$71.42
7D
4.7%
1Y
5.0%
ChampionX
Market Cap: US$5.0b
Provides chemistry solutions, artificial lift systems, and engineered equipment and technologies to oil and gas companies worldwide.
CHX
US$26.26
7D
7.8%
1Y
-23.6%
Icahn Enterprises
Market Cap: US$4.8b
Through its subsidiaries engages in the investment, energy, automotive, food packaging, real estate, home fashion and pharma in the United States and internationally.
IEP
US$9.19
7D
5.4%
1Y
-50.6%
Onto Innovation
Market Cap: US$4.6b
Engages in the design, development, manufacture, and support of process control tools that performs optical metrology and inspection worldwide.
ONTO
US$99.19
7D
-19.0%
1Y
-56.6%
BGC Group
Market Cap: US$4.5b
Operates as a financial brokerage and technology company in the United States, Europe, the Middle East, Africa, and the Asia Pacific.
BGC
US$9.34
7D
-1.6%
1Y
8.0%
Vaxcyte
Market Cap: US$4.1b
A clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.
PCVX
US$30.05
7D
2.8%
1Y
-55.4%
Krystal Biotech
Market Cap: US$4.0b
A commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.
KRYS
US$134.53
7D
-3.5%
1Y
-15.6%
Telephone and Data Systems
Market Cap: US$3.9b
A telecommunications company, provides communications services to consumer, business, and government in the United States.
TDS
US$33.24
7D
-2.3%
1Y
57.8%
Cytokinetics
Market Cap: US$3.8b
A late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States.
CYTK
US$30.61
7D
-9.9%
1Y
-48.4%
GEO Group
Market Cap: US$3.6b
Owns, leases, operates, and manages secure facilities, processing centers, and community-based reentry facilities in the United States, Australia, the United Kingdom, and South Africa.
GEO
US$26.59
7D
-12.4%
1Y
102.7%
Sarepta Therapeutics
Market Cap: US$3.6b
A commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases.
SRPT
US$36.20
7D
-22.6%
1Y
-72.7%
Avidity Biosciences
Market Cap: US$3.5b
A biopharmaceutical company, engages in the delivery of RNA therapeutics.
RNA
US$29.88
7D
13.8%
1Y
3.4%
Ultragenyx Pharmaceutical
Market Cap: US$3.4b
A biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific.
RARE
US$35.40
7D
1.0%
1Y
-13.6%
Zeta Global Holdings
Market Cap: US$3.4b
Operates an omnichannel data-driven cloud platform that provides enterprises with consumer intelligence and marketing automation software in the United States and internationally.
ZETA
US$14.91
7D
13.7%
1Y
-8.5%
Rigetti Computing
Market Cap: US$3.4b
Through its subsidiaries, builds quantum computers and the superconducting quantum processors the United States, the United Kingdom, rest of Europe, Asia, and internationally.
RGTI
US$9.87
7D
0.8%
1Y
647.3%
Akero Therapeutics
Market Cap: US$3.3b
Engages in the development of treatments for patients with serious metabolic diseases in the United States.
AKRO
US$40.01
7D
-4.8%
1Y
97.1%